Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Sarcoma 1Plasma cell 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × amrubicin × Breast × Clear all
NCT01033032 2022-05-03

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

SCRI Development Innovations, LLC

Phase 1/2 Completed
78 enrolled 15 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡